<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02839902</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-085-4002</org_study_id>
    <secondary_id>U1111-1185-0054</secondary_id>
    <secondary_id>JapicCTI-163322</secondary_id>
    <nct_id>NCT02839902</nct_id>
  </id_info>
  <brief_title>Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood</brief_title>
  <acronym>LOTUS</acronym>
  <official_title>Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the effects of 8-week treatment with omega-3-acid
      ethyl esters on the lipid and lipoprotein profile in the blood in hyperlipidemic patients
      receiving a HMG-CoA reductase inhibitor by use of HPLC in comparison with the control group
      of patients not treated with omega-3-acid ethyl esters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed to explore the effects of omega-3-acid ethyl esters on the lipid and
      lipoprotein profile in the blood in hyperlipidemic patients receiving a
      hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor in comparison with the control
      group of patients not treated with omega-3-acid ethyl esters in an unblinded manner by use of
      high performance liquid chromatography (HPLC) using highly-sensitive gel filtration columns,
      which is a technique for analyzing lipoprotein.

      Study participants who gave consent and were assessed as eligible in the eligibility
      assessment will be stratified by the factors of &quot;fasting triacylglycerol (TG; &lt;300 mg/dL or
      300 mg/dL≤) and age (&lt;65 years or 65 years≤) at the start of the screening period&quot; and
      allocated to either the group treated with omega-3-acid ethyl esters or the group not treated
      with omega-3-acid ethyl esters (1:1 ratio).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 27, 2016</start_date>
  <completion_date type="Actual">August 30, 2017</completion_date>
  <primary_completion_date type="Actual">August 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Small Dense Low Density Lipoprotein (sdLDL) Fraction</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>Major 4 lipid constituents refer to cholesterol, triglycerides, free cholesterol, and phospholipid. The reported data are percent of change from baseline in concentration of the each lipid constituents in sdLDL fraction at Week 4 and Week 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Changes From Baseline in Triglycerides (TG) to Cholesterol Ratio in sdLDL Fraction</measure>
    <time_frame>Baseline, Week 4, and Week 8</time_frame>
    <description>Reported data are percent of change from baseline in in TG to cholesterol ratio in sdLDL fraction at Week 4 and Week 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in Mean Particle Sizes of Small Dense Low Density Lipoprotein-cholesterol (sdLDL-C) and Low Density Lipoprotein-cholesterol (LDL-C) Monitored by Major 4 Lipid Constituents</measure>
    <time_frame>Baseline, Week 4, and Week 8</time_frame>
    <description>Reported data are percent of change from baseline in mean particle sizes of sdLDL-C and LDL-C monitored by major 4 lipid constituents (cholesterol, triglycerides, free cholesterol, and phospholipid) at Week 4 and Week 8. Here the data were consolidated from results of the two outcome measures (&quot;Change in mean particle sizes of sdLDL-C&quot; and &quot;Change in mean particle sizes of LDL-C&quot;) on initial registration information (see History of Change of registration) because sdLDL-C refers to LDL-C which is smaller particle size and heavier density.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Chylomicron (CM) Fraction</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>Major 4 lipid constituents refer to cholesterol, triglycerides, free cholesterol, and phospholipid. The reported data are percent of change from baseline in concentration of the each lipid constituents in CM fraction at Week 4 and Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Very Low-density Lipoprotein (VLDL) Fraction</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>Major 4 lipid constituents refer to cholesterol, triglycerides, free cholesterol, and phospholipid. The reported data are percent of change from baseline in concentration of the each lipid constituents in VLDL Fraction at Week 4 and Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Low-density Lipoprotein (LDL) Fraction</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>Major 4 lipid constituents refer to cholesterol, triglycerides, free cholesterol, and phospholipid. The reported data are percent of change from baseline in concentration of the each lipid constituents in LDL Fraction at Week 4 and Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in High-density Lipoprotein (HDL) Fraction</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>Major 4 lipid constituents refer to cholesterol, triglycerides, free cholesterol, and phospholipid. The reported data are percent of change from baseline in concentration of the each lipid constituents in HDL Fraction at Week 4 and Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes From Baseline in Concentration of Fatty Acids in Total Lipids</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>Fatty acids refer to the following 24 acids; Lauric acid, Myristic acid, Myristoleic acid, Palmitic acid, Palmitoleic acid, Stearic acid, Oleic acid, Linoleic acid, Gamma-linolenic acid, Linolenic acid, Arachic acid, Eicosenoic acid, Eicosadienoic acid, 5-8-11 Eicosatrienoic acid, Dihomo-gamma-linolenic acid, Arachidonic acid, Eicosapentaenoic acid, Behenic acid, Erucic acid, Docosatetraenoic acid, Docosapentaenoic acid, Lignoceric acid, Docosahexaenoic acid, and Nervonic acid. The reported data are percent of change from baseline in concentration of these fatty acids in total lipids at Week 4 and Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes From Baseline in Eicosatrienoic Acid to Arachidonic Acid (T/T) Ratio in Total Lipids</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>The reported data are percent of change from baseline in T/T ratio in total lipids at Week 4 and Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes From Baseline in Eicosapentaenoic Acid to Arachidonic Acid (EPA/AA) Ratio in Total Lipids</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>The reported data are percent of change from baseline in EPA/AA ratio in total lipids at Week 4 and Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes From Baseline in Eicosapentaenoic Acid Plus Docosahexaenoic Acid to Arachidonic Acid (EPA+DHA/AA) Ratio in Total Lipids</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>The reported data are percent of change from baseline in EPA+DHA/AA ratio in total lipids at Week 4 and Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes From Baseline in Docosahexaenoic Acid to Arachidonic Acid (DHA/AA) Ratio in Total Lipids</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>The reported data are percent of change from baseline in DHA/AA ratio in total lipids at Week 4 and Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Concentration of sd LDL-C in Total Lipids</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>There were no reporting data for this outcome measure because the data of change in mean concentration of sdLDL-C in total lipids were not collected and analyzed in this study finally. So here the data input for this outcome measure are NA for each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Concentration of Lipids in the Blood</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>Lipids on this outcome measure include Total cholesterol, Triacylglycerol (TG), HDL-C, non-HDL, and Remnant lipoprotein cholesterol (RemL-C). Reported data are percent of change in concentration of these lipids in the blood at Week 4 and Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Concentration of Apolipoproteins in the Blood</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>Apolipoproteins on this outcome measure include Apolipoprotein AI, AII, B, B-48, B-100, CII, CIII, CII/III, and E. Reported data are percent of change in concentration of these apolipoproteins in the blood at Week 4 and Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipoprotein Particle Numbers in the Blood</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>Reported data were percent of changes from baseline in lipoprotein particle numbers in the blood for 4 fractions (CM, VLDL, LDL, and HDL fractions). Data for this outcome measure was reported instead of the outcome measure title of &quot;Change from Baseline in particle number of lipids, apoprotein and lipoprotein&quot; on registration module (see History of Change of registration).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>TAK-085 4g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule is orally administered immediately after meal twice a daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-085</intervention_name>
    <description>Omega-3-acid ethyl esters (TAK-085) capsule</description>
    <arm_group_label>TAK-085 4g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not treated with omega-3-acid ethyl esters</intervention_name>
    <description>Not treated with omega-3-acid ethyl esters</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants diagnosed as hyperlipidemia.

          2. Participants constantly receiving a HMG-CoA reductase inhibitor at a stable dose for
             at least 4 weeks at the start of the observation period.

          3. Participants with fasting TG of 150≤ to &lt;400 mg/dL measured at the start of the
             observation period at Visit 1 (Week -4).

          4. Participants who, in the opinion of the principal investigator or the investigator,
             are capable of understanding the content of the clinical study and complying with the
             study protocol requirements.

          5. Participants who can provide written informed consent prior to the conduction of the
             clinical study procedures.

          6. Participants aged ≥20 years at the time of informed consent at Visit 1 (Week -4).

        Exclusion Criteria:

          1. Participants who had clinically significant hemorrhagic disorders (e.g., hemophilia,
             capillary fragility, gastrointestinal ulcer, urinary tract hemorrhage, hemoptysis, and
             vitreous hemorrhage) within 24 weeks prior to the start of the observation period, or
             those who concurrently have the above disorders.

          2. Participants who had thyroid disorders (hyperthyroidism or hypothyroidism) within 24
             weeks prior to the start of the observation period, those who concurrently have the
             above disorders, or those who are orally receiving a therapeutic drug for thyroid
             disorder.

          3. Participants in whom the type of HMG-CoA reductase inhibitors was changed within 12
             weeks prior to the start of observation period.

          4. Participants who received an eicosapentaenoic acid (EPA) preparation or an
             EPA/docosahexaenoic acid (DHA) preparation (including supplements) within 12 weeks
             prior to the start of observation period.

          5. Participants who started antidyslipidemic agents within 4 weeks prior to the start of
             observation period.

          6. Participants with severe hepatic impairment (e.g., Child-Pugh classification C).

          7. Participants who were previously diagnosed as lipoprotein lipase deficiency or
             apoprotein C-II deficiency.

          8. Participants who are concurrently having Cushing's syndrome, uremia, systemic lupus
             erythematosus (SLE), or serum dysproteinemia.

          9. Diabetic participants who are currently receiving thiazolidine or insulin.

         10. Participants who are concurrently having hypertension of grade IIINote 1). Note 1:
             Participants with systolic blood pressure of ≥180 mm Hg or diastolic blood pressure of
             ≥110 mm Hg regardless of treatment with antihypertensive drugs.

         11. Participants who are habitual drinkers drinking an average of over 100 mL per day
             (expressed in terms of quantity of alcohol), or participants with or with a history of
             drug abuse or addiction.

         12. Pregnant, lactating or postmenopausal women.

         13. Participants with a history of hypersensitivity or allergy for omega-3-acid ethyl
             esters.

         14. Participants participating in other clinical studies.

         15. Participants assessed ineligible in the study by the principal investigator or the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Noda</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koga</city>
        <state>Ibaragi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moriguchi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fujimi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <results_first_submitted>August 28, 2018</results_first_submitted>
  <results_first_submitted_qc>August 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 11, 2019</results_first_posted>
  <last_update_submitted>August 28, 2018</last_update_submitted>
  <last_update_submitted_qc>August 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 7, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT02839902/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT02839902/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 7 investigative sites in Japan, from 27 December 2016 to 30 August 2017.</recruitment_details>
      <pre_assignment_details>Participants with a historical diagnosis of hyperlipidemia who were inadequately controlled while receiving a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor were enrolled in one of two groups, treatment group with omega-3-acid ethyl esters (TAK-085) 2 grams (g) and treatment group without TAK-085 (Control Group).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TAK-085 4 g</title>
          <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>TAK-085 4 g</title>
          <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" spread="11.28"/>
                    <measurement group_id="B2" value="62.3" spread="11.67"/>
                    <measurement group_id="B3" value="61.5" spread="11.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Centimeters (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.9" spread="6.05"/>
                    <measurement group_id="B2" value="167.7" spread="7.55"/>
                    <measurement group_id="B3" value="168.2" spread="6.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.93" spread="9.784"/>
                    <measurement group_id="B2" value="77.13" spread="12.507"/>
                    <measurement group_id="B3" value="77.49" spread="11.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index = weight (kg)/[height (m)^2]</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.27" spread="2.791"/>
                    <measurement group_id="B2" value="27.39" spread="3.746"/>
                    <measurement group_id="B3" value="27.34" spread="3.317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Hyperlipemia</title>
          <description>Mean duration between start of study and first time of diagnosis of hyperlipemia was reported.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.05" spread="7.590"/>
                    <measurement group_id="B2" value="7.76" spread="5.847"/>
                    <measurement group_id="B3" value="9.25" spread="6.828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Frequency of Fish Intake</title>
          <description>Participants were asked a question about frequency of consumption of fish and answered from 4 types of the answers; Almost Every Day, About Every 2 Days, About Once or Twice per Week, and Rarely. Reported data were the number of participants who selected from 4 answers.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Almost Every Day</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>About Every Two Days</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>About Once or Twice Per Week</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rarely</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Never smoked</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Current smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ex-smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drinking habit</title>
          <description>Participants who answered Yes or No for a question &quot;Drink Alcohol Almost Every Day?&quot; were reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Triglycerides</title>
          <units>Milligram (mg)/deciliter (dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="208.0" spread="74.05"/>
                    <measurement group_id="B2" value="214.7" spread="73.12"/>
                    <measurement group_id="B3" value="211.7" spread="72.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cholesterol Concentration in Small Dense Low Density Lipoprotein (sdLDL) Fraction</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.285" spread="5.9109"/>
                    <measurement group_id="B2" value="32.981" spread="9.1346"/>
                    <measurement group_id="B3" value="31.760" spread="7.8879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides Concentration in sdLDL Fraction</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.778" spread="1.8022"/>
                    <measurement group_id="B2" value="7.320" spread="2.0727"/>
                    <measurement group_id="B3" value="7.074" spread="1.9556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Free Cholesterol Concentration in sdLDL Fraction</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.670" spread="1.6883"/>
                    <measurement group_id="B2" value="9.353" spread="2.3705"/>
                    <measurement group_id="B3" value="9.044" spread="2.0986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Phospholipid Concentration in sdLDL Fraction</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.526" spread="5.1749"/>
                    <measurement group_id="B2" value="33.860" spread="7.9633"/>
                    <measurement group_id="B3" value="32.803" spread="6.8824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Particle Size of LDL(Cholesterol Monitor)</title>
          <units>Nanometer (nm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.712" spread="0.4301"/>
                    <measurement group_id="B2" value="25.681" spread="0.4087"/>
                    <measurement group_id="B3" value="25.695" spread="0.4148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Particle Size of LDL (Triglycerides Monitor)</title>
          <population>Population Analysis Description: The number analyzed is the number of participants with data available for analysis.</population>
          <units>nm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.378" spread="1.0152"/>
                    <measurement group_id="B2" value="29.005" spread="0.8946"/>
                    <measurement group_id="B3" value="29.173" spread="0.9442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Particle Size of LDL (Free Cholesterol Monitor)</title>
          <units>nm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.560" spread="0.4403"/>
                    <measurement group_id="B2" value="25.492" spread="0.4263"/>
                    <measurement group_id="B3" value="25.523" spread="0.4299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Particle Size of LDL (Phospholipid Monitor)</title>
          <units>nm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.335" spread="0.4431"/>
                    <measurement group_id="B2" value="25.263" spread="0.3945"/>
                    <measurement group_id="B3" value="25.296" spread="0.4147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Small Dense Low Density Lipoprotein (sdLDL) Fraction</title>
        <description>Major 4 lipid constituents refer to cholesterol, triglycerides, free cholesterol, and phospholipid. The reported data are percent of change from baseline in concentration of the each lipid constituents in sdLDL fraction at Week 4 and Week 8.</description>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 4 g</title>
            <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Small Dense Low Density Lipoprotein (sdLDL) Fraction</title>
          <description>Major 4 lipid constituents refer to cholesterol, triglycerides, free cholesterol, and phospholipid. The reported data are percent of change from baseline in concentration of the each lipid constituents in sdLDL fraction at Week 4 and Week 8.</description>
          <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
          <units>Percent of Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.50" spread="15.745"/>
                    <measurement group_id="O2" value="5.05" spread="11.401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.35" spread="13.519"/>
                    <measurement group_id="O2" value="4.64" spread="17.845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.87" spread="22.917"/>
                    <measurement group_id="O2" value="9.71" spread="23.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.50" spread="22.615"/>
                    <measurement group_id="O2" value="2.74" spread="20.317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Cholesterol at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.32" spread="12.483"/>
                    <measurement group_id="O2" value="2.14" spread="14.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Cholesterol at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.94" spread="16.639"/>
                    <measurement group_id="O2" value="3.42" spread="14.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phospholipid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.31" spread="11.396"/>
                    <measurement group_id="O2" value="2.10" spread="11.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phospholipid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.37" spread="13.919"/>
                    <measurement group_id="O2" value="1.09" spread="13.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The least square (LS) mean percentage change was compared between treatment groups with cholesterol concentration in sd LDL fraction at Week 8 using an ANCOVA model.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Least square (LS) mean difference</non_inferiority_desc>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <param_type>Least square (LS) mean difference</param_type>
            <param_value>-17.147</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.344</ci_lower_limit>
            <ci_upper_limit>-7.950</ci_upper_limit>
            <estimate_desc>TAK-085 4 g - Control Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The least square (LS) mean percentage change was compared between treatment groups with triglycerides concentration in sd LDL fraction at Week 8 using an ANCOVA model.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Least square (LS) mean difference</non_inferiority_desc>
            <p_value>0.1141</p_value>
            <method>ANCOVA</method>
            <param_type>Least square (LS) mean difference</param_type>
            <param_value>-9.774</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.986</ci_lower_limit>
            <ci_upper_limit>2.439</ci_upper_limit>
            <estimate_desc>TAK-085 4 g - Control Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The least square (LS) mean percentage change was compared between treatment groups with free cholesterol concentration in sd LDL fraction at Week 8 using an ANCOVA model.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Least square (LS) mean difference</non_inferiority_desc>
            <p_value>0.0248</p_value>
            <method>ANCOVA</method>
            <param_type>Least square (LS) mean difference</param_type>
            <param_value>-10.246</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.143</ci_lower_limit>
            <ci_upper_limit>-1.349</ci_upper_limit>
            <estimate_desc>TAK-085 4 g - Control Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The least square (LS) mean percentage change was compared between treatment groups with phospholipid concentration in sd LDL fraction at Week 8 using an ANCOVA model.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Least square (LS) mean difference</non_inferiority_desc>
            <p_value>0.0047</p_value>
            <method>ANCOVA</method>
            <param_type>Least square (LS) mean difference</param_type>
            <param_value>-11.511</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.340</ci_lower_limit>
            <ci_upper_limit>-3.682</ci_upper_limit>
            <estimate_desc>TAK-085 4 g - Control Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Changes From Baseline in Triglycerides (TG) to Cholesterol Ratio in sdLDL Fraction</title>
        <description>Reported data are percent of change from baseline in in TG to cholesterol ratio in sdLDL fraction at Week 4 and Week 8.</description>
        <time_frame>Baseline, Week 4, and Week 8</time_frame>
        <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 4 g</title>
            <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes From Baseline in Triglycerides (TG) to Cholesterol Ratio in sdLDL Fraction</title>
          <description>Reported data are percent of change from baseline in in TG to cholesterol ratio in sdLDL fraction at Week 4 and Week 8.</description>
          <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
          <units>Percent of Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" spread="21.423"/>
                    <measurement group_id="O2" value="5.66" spread="25.908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.64" spread="31.398"/>
                    <measurement group_id="O2" value="-0.94" spread="17.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The least square (LS) mean percentage change was compared between treatment groups with TG to cholesterol ratio in sd LDL fraction at Week 8 using an ANCOVA model.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Least square (LS) mean difference</non_inferiority_desc>
            <p_value>0.1826</p_value>
            <method>ANCOVA</method>
            <param_type>Least square (LS) mean difference</param_type>
            <param_value>9.499</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.623</ci_lower_limit>
            <ci_upper_limit>23.622</ci_upper_limit>
            <estimate_desc>TAK-085 4 g - Control Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Mean Particle Sizes of Small Dense Low Density Lipoprotein-cholesterol (sdLDL-C) and Low Density Lipoprotein-cholesterol (LDL-C) Monitored by Major 4 Lipid Constituents</title>
        <description>Reported data are percent of change from baseline in mean particle sizes of sdLDL-C and LDL-C monitored by major 4 lipid constituents (cholesterol, triglycerides, free cholesterol, and phospholipid) at Week 4 and Week 8. Here the data were consolidated from results of the two outcome measures (&quot;Change in mean particle sizes of sdLDL-C&quot; and &quot;Change in mean particle sizes of LDL-C&quot;) on initial registration information (see History of Change of registration) because sdLDL-C refers to LDL-C which is smaller particle size and heavier density.</description>
        <time_frame>Baseline, Week 4, and Week 8</time_frame>
        <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 4 g</title>
            <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean Particle Sizes of Small Dense Low Density Lipoprotein-cholesterol (sdLDL-C) and Low Density Lipoprotein-cholesterol (LDL-C) Monitored by Major 4 Lipid Constituents</title>
          <description>Reported data are percent of change from baseline in mean particle sizes of sdLDL-C and LDL-C monitored by major 4 lipid constituents (cholesterol, triglycerides, free cholesterol, and phospholipid) at Week 4 and Week 8. Here the data were consolidated from results of the two outcome measures (&quot;Change in mean particle sizes of sdLDL-C&quot; and &quot;Change in mean particle sizes of LDL-C&quot;) on initial registration information (see History of Change of registration) because sdLDL-C refers to LDL-C which is smaller particle size and heavier density.</description>
          <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
          <units>Percent of Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (Cholesterol Monitor)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="1.217"/>
                    <measurement group_id="O2" value="-0.39" spread="0.820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Cholesterol Monitor)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="1.192"/>
                    <measurement group_id="O2" value="-0.08" spread="1.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Triglycerides Monitor)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="6.026"/>
                    <measurement group_id="O2" value="-0.06" spread="1.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Triglycerides Monitor)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="2.715"/>
                    <measurement group_id="O2" value="0.52" spread="3.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Free Cholesterol Monitor)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="1.247"/>
                    <measurement group_id="O2" value="-0.16" spread="0.953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Free Cholesterol Monitor)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="1.407"/>
                    <measurement group_id="O2" value="0.07" spread="1.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Phospholipid Monitor)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="1.464"/>
                    <measurement group_id="O2" value="-0.23" spread="1.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Phospholipid Monitor)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="1.316"/>
                    <measurement group_id="O2" value="0.09" spread="1.431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The least square (LS) mean percentage change was compared between treatment groups with particle size (nm) of LDL at Week 8 monitored by cholesterol using an ANCOVA model.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Least square (LS) mean difference</non_inferiority_desc>
            <p_value>0.0040</p_value>
            <method>ANCOVA</method>
            <param_type>Least square (LS) mean difference</param_type>
            <param_value>1.066</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.356</ci_lower_limit>
            <ci_upper_limit>1.776</ci_upper_limit>
            <estimate_desc>TAK-085 4 g - Control Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The least square (LS) mean percentage change was compared between treatment groups with particle size (nm) of LDL at Week 8 monitored by triglycerides using an ANCOVA model.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Least square (LS) mean difference</non_inferiority_desc>
            <p_value>0.4428</p_value>
            <method>ANCOVA</method>
            <param_type>Least square (LS) mean difference</param_type>
            <param_value>1.553</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.884</ci_lower_limit>
            <ci_upper_limit>5.991</ci_upper_limit>
            <estimate_desc>TAK-085 4 g - Control Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The least square (LS) mean percentage change was compared between treatment groups with particle size (nm) of LDL at Week 8 monitored by free cholesterol using an ANCOVA model.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Least square (LS) mean difference</non_inferiority_desc>
            <p_value>0.0570</p_value>
            <method>ANCOVA</method>
            <param_type>Least square (LS) mean difference</param_type>
            <param_value>0.760</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.024</ci_lower_limit>
            <ci_upper_limit>1.544</ci_upper_limit>
            <estimate_desc>TAK-085 4 g - Control Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The least square (LS) mean percentage change was compared between treatment groups with particle size (nm) of LDL at Week 8 monitored by phospholipid using an ANCOVA model.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Least square (LS) mean difference</non_inferiority_desc>
            <p_value>0.0360</p_value>
            <method>ANCOVA</method>
            <param_type>Least square (LS) mean difference</param_type>
            <param_value>0.838</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.057</ci_lower_limit>
            <ci_upper_limit>1.620</ci_upper_limit>
            <estimate_desc>TAK-085 4 g - Control Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Chylomicron (CM) Fraction</title>
        <description>Major 4 lipid constituents refer to cholesterol, triglycerides, free cholesterol, and phospholipid. The reported data are percent of change from baseline in concentration of the each lipid constituents in CM fraction at Week 4 and Week 8.</description>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 4 g</title>
            <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Chylomicron (CM) Fraction</title>
          <description>Major 4 lipid constituents refer to cholesterol, triglycerides, free cholesterol, and phospholipid. The reported data are percent of change from baseline in concentration of the each lipid constituents in CM fraction at Week 4 and Week 8.</description>
          <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
          <units>Percent of Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.03" spread="53.008"/>
                    <measurement group_id="O2" value="47.42" spread="149.946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.92" spread="60.170"/>
                    <measurement group_id="O2" value="-0.68" spread="65.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.22" spread="49.604"/>
                    <measurement group_id="O2" value="42.62" spread="132.804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.32" spread="52.994"/>
                    <measurement group_id="O2" value="-3.74" spread="55.812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Cholesterol at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.13" spread="50.570"/>
                    <measurement group_id="O2" value="60.20" spread="189.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Cholesterol at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.33" spread="65.974"/>
                    <measurement group_id="O2" value="2.37" spread="71.895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phospholipid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.25" spread="61.678"/>
                    <measurement group_id="O2" value="48.94" spread="118.843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phospholipid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.00" spread="64.130"/>
                    <measurement group_id="O2" value="1.15" spread="92.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Very Low-density Lipoprotein (VLDL) Fraction</title>
        <description>Major 4 lipid constituents refer to cholesterol, triglycerides, free cholesterol, and phospholipid. The reported data are percent of change from baseline in concentration of the each lipid constituents in VLDL Fraction at Week 4 and Week 8.</description>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 4 g</title>
            <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Very Low-density Lipoprotein (VLDL) Fraction</title>
          <description>Major 4 lipid constituents refer to cholesterol, triglycerides, free cholesterol, and phospholipid. The reported data are percent of change from baseline in concentration of the each lipid constituents in VLDL Fraction at Week 4 and Week 8.</description>
          <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
          <units>Percent of Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.45" spread="17.089"/>
                    <measurement group_id="O2" value="5.45" spread="15.255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.16" spread="19.449"/>
                    <measurement group_id="O2" value="1.03" spread="14.717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.21" spread="23.536"/>
                    <measurement group_id="O2" value="7.24" spread="28.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.26" spread="24.705"/>
                    <measurement group_id="O2" value="-1.32" spread="20.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Cholesterol at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.06" spread="19.539"/>
                    <measurement group_id="O2" value="6.99" spread="20.379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Cholesterol at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.48" spread="24.694"/>
                    <measurement group_id="O2" value="0.64" spread="17.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phospholipid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.78" spread="19.839"/>
                    <measurement group_id="O2" value="5.99" spread="19.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phospholipid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.49" spread="22.717"/>
                    <measurement group_id="O2" value="-1.09" spread="16.446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Low-density Lipoprotein (LDL) Fraction</title>
        <description>Major 4 lipid constituents refer to cholesterol, triglycerides, free cholesterol, and phospholipid. The reported data are percent of change from baseline in concentration of the each lipid constituents in LDL Fraction at Week 4 and Week 8.</description>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 4 g</title>
            <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in Low-density Lipoprotein (LDL) Fraction</title>
          <description>Major 4 lipid constituents refer to cholesterol, triglycerides, free cholesterol, and phospholipid. The reported data are percent of change from baseline in concentration of the each lipid constituents in LDL Fraction at Week 4 and Week 8.</description>
          <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
          <units>Percent of Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.40" spread="10.300"/>
                    <measurement group_id="O2" value="1.44" spread="11.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.25" spread="12.087"/>
                    <measurement group_id="O2" value="3.45" spread="11.789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="13.307"/>
                    <measurement group_id="O2" value="3.82" spread="10.813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="15.034"/>
                    <measurement group_id="O2" value="2.19" spread="12.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Cholesterol at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="12.581"/>
                    <measurement group_id="O2" value="0.30" spread="13.908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Cholesterol at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="15.395"/>
                    <measurement group_id="O2" value="3.32" spread="12.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phospholipid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.94" spread="8.257"/>
                    <measurement group_id="O2" value="0.29" spread="9.809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phospholipid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.80" spread="10.561"/>
                    <measurement group_id="O2" value="1.58" spread="9.817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in High-density Lipoprotein (HDL) Fraction</title>
        <description>Major 4 lipid constituents refer to cholesterol, triglycerides, free cholesterol, and phospholipid. The reported data are percent of change from baseline in concentration of the each lipid constituents in HDL Fraction at Week 4 and Week 8.</description>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 4 g</title>
            <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes From Baseline in Concentration of Major 4 Lipid Constituents in High-density Lipoprotein (HDL) Fraction</title>
          <description>Major 4 lipid constituents refer to cholesterol, triglycerides, free cholesterol, and phospholipid. The reported data are percent of change from baseline in concentration of the each lipid constituents in HDL Fraction at Week 4 and Week 8.</description>
          <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
          <units>Percent of Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.49" spread="7.316"/>
                    <measurement group_id="O2" value="0.64" spread="8.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.24" spread="9.567"/>
                    <measurement group_id="O2" value="1.48" spread="8.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.07" spread="23.323"/>
                    <measurement group_id="O2" value="6.20" spread="23.726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.99" spread="34.397"/>
                    <measurement group_id="O2" value="0.91" spread="19.979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Cholesterol at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.56" spread="9.832"/>
                    <measurement group_id="O2" value="3.29" spread="9.708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Cholesterol at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.31" spread="12.969"/>
                    <measurement group_id="O2" value="5.61" spread="12.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phospholipid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.47" spread="7.169"/>
                    <measurement group_id="O2" value="-2.32" spread="8.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phospholipid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.45" spread="10.432"/>
                    <measurement group_id="O2" value="-3.40" spread="10.212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Changes From Baseline in Concentration of Fatty Acids in Total Lipids</title>
        <description>Fatty acids refer to the following 24 acids; Lauric acid, Myristic acid, Myristoleic acid, Palmitic acid, Palmitoleic acid, Stearic acid, Oleic acid, Linoleic acid, Gamma-linolenic acid, Linolenic acid, Arachic acid, Eicosenoic acid, Eicosadienoic acid, 5-8-11 Eicosatrienoic acid, Dihomo-gamma-linolenic acid, Arachidonic acid, Eicosapentaenoic acid, Behenic acid, Erucic acid, Docosatetraenoic acid, Docosapentaenoic acid, Lignoceric acid, Docosahexaenoic acid, and Nervonic acid. The reported data are percent of change from baseline in concentration of these fatty acids in total lipids at Week 4 and Week 8.</description>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 4 g</title>
            <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes From Baseline in Concentration of Fatty Acids in Total Lipids</title>
          <description>Fatty acids refer to the following 24 acids; Lauric acid, Myristic acid, Myristoleic acid, Palmitic acid, Palmitoleic acid, Stearic acid, Oleic acid, Linoleic acid, Gamma-linolenic acid, Linolenic acid, Arachic acid, Eicosenoic acid, Eicosadienoic acid, 5-8-11 Eicosatrienoic acid, Dihomo-gamma-linolenic acid, Arachidonic acid, Eicosapentaenoic acid, Behenic acid, Erucic acid, Docosatetraenoic acid, Docosapentaenoic acid, Lignoceric acid, Docosahexaenoic acid, and Nervonic acid. The reported data are percent of change from baseline in concentration of these fatty acids in total lipids at Week 4 and Week 8.</description>
          <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
          <units>Percent of Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lauric Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.26" spread="56.101"/>
                    <measurement group_id="O2" value="50.65" spread="86.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lauric Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.84" spread="85.494"/>
                    <measurement group_id="O2" value="34.60" spread="138.684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myristic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.37" spread="26.046"/>
                    <measurement group_id="O2" value="24.68" spread="54.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myristic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.31" spread="33.571"/>
                    <measurement group_id="O2" value="5.96" spread="32.534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myristoleic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.40" spread="25.830"/>
                    <measurement group_id="O2" value="32.50" spread="77.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myristoleic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.54" spread="100.145"/>
                    <measurement group_id="O2" value="-0.55" spread="37.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palmitic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.49" spread="20.682"/>
                    <measurement group_id="O2" value="5.77" spread="17.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palmitic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.62" spread="22.355"/>
                    <measurement group_id="O2" value="-2.63" spread="15.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palmitoleic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.35" spread="22.371"/>
                    <measurement group_id="O2" value="5.53" spread="29.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palmitoleic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.25" spread="27.584"/>
                    <measurement group_id="O2" value="-1.17" spread="22.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stearic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.74" spread="22.322"/>
                    <measurement group_id="O2" value="4.03" spread="16.408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stearic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.17" spread="24.102"/>
                    <measurement group_id="O2" value="0.12" spread="14.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oleic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.77" spread="23.295"/>
                    <measurement group_id="O2" value="3.28" spread="19.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oleic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.77" spread="25.958"/>
                    <measurement group_id="O2" value="-4.90" spread="15.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Linoleic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.47" spread="17.286"/>
                    <measurement group_id="O2" value="2.93" spread="12.616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Linoleic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.84" spread="16.303"/>
                    <measurement group_id="O2" value="-0.33" spread="14.748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma-linolenic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.84" spread="17.846"/>
                    <measurement group_id="O2" value="7.82" spread="35.906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma-linolenic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.21" spread="19.170"/>
                    <measurement group_id="O2" value="-1.63" spread="23.426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Linolenic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.50" spread="26.598"/>
                    <measurement group_id="O2" value="12.09" spread="34.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Linolenic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.27" spread="30.301"/>
                    <measurement group_id="O2" value="-0.50" spread="25.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arachic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.59" spread="32.158"/>
                    <measurement group_id="O2" value="8.20" spread="35.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arachic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.11" spread="43.510"/>
                    <measurement group_id="O2" value="2.01" spread="32.969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eicosenoic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.66" spread="30.315"/>
                    <measurement group_id="O2" value="6.82" spread="41.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eicosenoic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.43" spread="28.872"/>
                    <measurement group_id="O2" value="0.80" spread="27.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eicosadienoic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.82" spread="18.803"/>
                    <measurement group_id="O2" value="0.31" spread="14.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eicosadienoic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.50" spread="21.967"/>
                    <measurement group_id="O2" value="-3.17" spread="18.978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-8-11 Eicosatrienoic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.51" spread="23.478"/>
                    <measurement group_id="O2" value="17.71" spread="68.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-8-11 Eicosatrienoic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.16" spread="24.514"/>
                    <measurement group_id="O2" value="13.24" spread="38.481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihomo-gamma-linolenic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.14" spread="15.452"/>
                    <measurement group_id="O2" value="0.89" spread="17.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihomo-gamma-linolenic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.18" spread="15.933"/>
                    <measurement group_id="O2" value="1.98" spread="22.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arachidonic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.23" spread="11.911"/>
                    <measurement group_id="O2" value="-1.97" spread="13.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arachidonic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.35" spread="14.448"/>
                    <measurement group_id="O2" value="-2.37" spread="13.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eicosapentaenoic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224.30" spread="155.842"/>
                    <measurement group_id="O2" value="16.58" spread="53.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eicosapentaenoic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238.48" spread="211.242"/>
                    <measurement group_id="O2" value="29.05" spread="83.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Behenic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.33" spread="47.184"/>
                    <measurement group_id="O2" value="-0.72" spread="36.672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Behenic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="48.418"/>
                    <measurement group_id="O2" value="4.09" spread="39.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erucic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.58" spread="279.981"/>
                    <measurement group_id="O2" value="91.40" spread="214.836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erucic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.05" spread="71.360"/>
                    <measurement group_id="O2" value="139.93" spread="376.748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Docosatetraenoic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.43" spread="17.765"/>
                    <measurement group_id="O2" value="4.94" spread="23.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Docosatetraenoic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.74" spread="17.764"/>
                    <measurement group_id="O2" value="1.07" spread="21.927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Docosapentaenoic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.16" spread="27.789"/>
                    <measurement group_id="O2" value="5.83" spread="22.423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Docosapentaenoic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.89" spread="33.735"/>
                    <measurement group_id="O2" value="5.78" spread="25.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lignoceric Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.06" spread="20.062"/>
                    <measurement group_id="O2" value="-2.00" spread="20.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lignoceric Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.01" spread="25.548"/>
                    <measurement group_id="O2" value="-2.33" spread="24.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Docosahexaenoic Acid at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.71" spread="25.367"/>
                    <measurement group_id="O2" value="3.10" spread="20.643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Docosahexaenoic Acid at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.00" spread="41.055"/>
                    <measurement group_id="O2" value="7.32" spread="27.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervonic Acid Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.61" spread="14.334"/>
                    <measurement group_id="O2" value="5.98" spread="25.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervonic Acid Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.82" spread="15.480"/>
                    <measurement group_id="O2" value="13.04" spread="29.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Changes From Baseline in Eicosatrienoic Acid to Arachidonic Acid (T/T) Ratio in Total Lipids</title>
        <description>The reported data are percent of change from baseline in T/T ratio in total lipids at Week 4 and Week 8.</description>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 4 g</title>
            <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes From Baseline in Eicosatrienoic Acid to Arachidonic Acid (T/T) Ratio in Total Lipids</title>
          <description>The reported data are percent of change from baseline in T/T ratio in total lipids at Week 4 and Week 8.</description>
          <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
          <units>Percent of Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.81" spread="23.814"/>
                    <measurement group_id="O2" value="8.62" spread="35.529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.50" spread="22.656"/>
                    <measurement group_id="O2" value="12.07" spread="43.620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Changes From Baseline in Eicosapentaenoic Acid to Arachidonic Acid (EPA/AA) Ratio in Total Lipids</title>
        <description>The reported data are percent of change from baseline in EPA/AA ratio in total lipids at Week 4 and Week 8.</description>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 4 g</title>
            <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes From Baseline in Eicosapentaenoic Acid to Arachidonic Acid (EPA/AA) Ratio in Total Lipids</title>
          <description>The reported data are percent of change from baseline in EPA/AA ratio in total lipids at Week 4 and Week 8.</description>
          <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
          <units>Percent of Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293.83" spread="185.305"/>
                    <measurement group_id="O2" value="18.98" spread="47.676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317.31" spread="212.306"/>
                    <measurement group_id="O2" value="31.77" spread="75.839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Changes From Baseline in Eicosapentaenoic Acid Plus Docosahexaenoic Acid to Arachidonic Acid (EPA+DHA/AA) Ratio in Total Lipids</title>
        <description>The reported data are percent of change from baseline in EPA+DHA/AA ratio in total lipids at Week 4 and Week 8.</description>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 4 g</title>
            <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes From Baseline in Eicosapentaenoic Acid Plus Docosahexaenoic Acid to Arachidonic Acid (EPA+DHA/AA) Ratio in Total Lipids</title>
          <description>The reported data are percent of change from baseline in EPA+DHA/AA ratio in total lipids at Week 4 and Week 8.</description>
          <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
          <units>Percent of Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.68" spread="57.033"/>
                    <measurement group_id="O2" value="8.87" spread="28.154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.20" spread="76.024"/>
                    <measurement group_id="O2" value="14.29" spread="34.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Changes From Baseline in Docosahexaenoic Acid to Arachidonic Acid (DHA/AA) Ratio in Total Lipids</title>
        <description>The reported data are percent of change from baseline in DHA/AA ratio in total lipids at Week 4 and Week 8.</description>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 4 g</title>
            <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes From Baseline in Docosahexaenoic Acid to Arachidonic Acid (DHA/AA) Ratio in Total Lipids</title>
          <description>The reported data are percent of change from baseline in DHA/AA ratio in total lipids at Week 4 and Week 8.</description>
          <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
          <units>Percent of Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.80" spread="31.135"/>
                    <measurement group_id="O2" value="6.22" spread="22.634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.11" spread="43.927"/>
                    <measurement group_id="O2" value="10.29" spread="25.525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Concentration of sd LDL-C in Total Lipids</title>
        <description>There were no reporting data for this outcome measure because the data of change in mean concentration of sdLDL-C in total lipids were not collected and analyzed in this study finally. So here the data input for this outcome measure are NA for each arm.</description>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>There were no reporting data for this outcome measure because the data of change in mean concentration of sdLDL-C in total lipids were not collected and analyzed in this study finally.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 4 g</title>
            <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Concentration of sd LDL-C in Total Lipids</title>
          <description>There were no reporting data for this outcome measure because the data of change in mean concentration of sdLDL-C in total lipids were not collected and analyzed in this study finally. So here the data input for this outcome measure are NA for each arm.</description>
          <population>There were no reporting data for this outcome measure because the data of change in mean concentration of sdLDL-C in total lipids were not collected and analyzed in this study finally.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Concentration of Lipids in the Blood</title>
        <description>Lipids on this outcome measure include Total cholesterol, Triacylglycerol (TG), HDL-C, non-HDL, and Remnant lipoprotein cholesterol (RemL-C). Reported data are percent of change in concentration of these lipids in the blood at Week 4 and Week 8.</description>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 4 g</title>
            <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Concentration of Lipids in the Blood</title>
          <description>Lipids on this outcome measure include Total cholesterol, Triacylglycerol (TG), HDL-C, non-HDL, and Remnant lipoprotein cholesterol (RemL-C). Reported data are percent of change in concentration of these lipids in the blood at Week 4 and Week 8.</description>
          <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
          <units>Percent of Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.74" spread="7.680"/>
                    <measurement group_id="O2" value="2.07" spread="8.336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.07" spread="8.325"/>
                    <measurement group_id="O2" value="1.43" spread="8.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.57" spread="27.101"/>
                    <measurement group_id="O2" value="9.60" spread="34.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.51" spread="32.860"/>
                    <measurement group_id="O2" value="-2.49" spread="22.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C (Direct) at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="8.290"/>
                    <measurement group_id="O2" value="0.70" spread="9.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C (Direct) at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="10.575"/>
                    <measurement group_id="O2" value="1.16" spread="8.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.71" spread="10.152"/>
                    <measurement group_id="O2" value="2.65" spread="9.978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.30" spread="11.473"/>
                    <measurement group_id="O2" value="2.07" spread="10.898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RemL-C at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.62" spread="29.222"/>
                    <measurement group_id="O2" value="15.84" spread="47.272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RemL-C at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.07" spread="38.146"/>
                    <measurement group_id="O2" value="-4.89" spread="27.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Concentration of Apolipoproteins in the Blood</title>
        <description>Apolipoproteins on this outcome measure include Apolipoprotein AI, AII, B, B-48, B-100, CII, CIII, CII/III, and E. Reported data are percent of change in concentration of these apolipoproteins in the blood at Week 4 and Week 8.</description>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 4 g</title>
            <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Concentration of Apolipoproteins in the Blood</title>
          <description>Apolipoproteins on this outcome measure include Apolipoprotein AI, AII, B, B-48, B-100, CII, CIII, CII/III, and E. Reported data are percent of change in concentration of these apolipoproteins in the blood at Week 4 and Week 8.</description>
          <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
          <units>Percent of Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Apolipoprotein AI at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.54" spread="5.068"/>
                    <measurement group_id="O2" value="1.39" spread="5.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein AI at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.25" spread="7.541"/>
                    <measurement group_id="O2" value="0.30" spread="6.540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein AII at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.56" spread="6.117"/>
                    <measurement group_id="O2" value="2.72" spread="7.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein AII at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.17" spread="7.326"/>
                    <measurement group_id="O2" value="2.86" spread="8.773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein B at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.48" spread="7.515"/>
                    <measurement group_id="O2" value="2.14" spread="8.674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein B at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.57" spread="9.763"/>
                    <measurement group_id="O2" value="1.63" spread="8.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein B-48 at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.38" spread="41.138"/>
                    <measurement group_id="O2" value="39.56" spread="84.921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein B-48 at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.50" spread="35.739"/>
                    <measurement group_id="O2" value="28.49" spread="71.554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein B-100 at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.30" spread="13.124"/>
                    <measurement group_id="O2" value="0.79" spread="9.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein B-100 at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.09" spread="13.453"/>
                    <measurement group_id="O2" value="2.39" spread="14.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein CII at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.69" spread="15.395"/>
                    <measurement group_id="O2" value="8.07" spread="16.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein CII at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.80" spread="17.579"/>
                    <measurement group_id="O2" value="6.04" spread="21.676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein CIII at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.29" spread="15.338"/>
                    <measurement group_id="O2" value="7.57" spread="15.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein CIII at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.14" spread="15.585"/>
                    <measurement group_id="O2" value="3.01" spread="16.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein CII/III at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.02" spread="13.076"/>
                    <measurement group_id="O2" value="1.58" spread="18.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein CII/III at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.02" spread="14.231"/>
                    <measurement group_id="O2" value="3.36" spread="16.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein E at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="19.222"/>
                    <measurement group_id="O2" value="4.38" spread="15.518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein E at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.24" spread="18.788"/>
                    <measurement group_id="O2" value="0.30" spread="13.578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipoprotein Particle Numbers in the Blood</title>
        <description>Reported data were percent of changes from baseline in lipoprotein particle numbers in the blood for 4 fractions (CM, VLDL, LDL, and HDL fractions). Data for this outcome measure was reported instead of the outcome measure title of &quot;Change from Baseline in particle number of lipids, apoprotein and lipoprotein&quot; on registration module (see History of Change of registration).</description>
        <time_frame>Baseline, Week 4 and Week 8</time_frame>
        <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-085 4 g</title>
            <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipoprotein Particle Numbers in the Blood</title>
          <description>Reported data were percent of changes from baseline in lipoprotein particle numbers in the blood for 4 fractions (CM, VLDL, LDL, and HDL fractions). Data for this outcome measure was reported instead of the outcome measure title of &quot;Change from Baseline in particle number of lipids, apoprotein and lipoprotein&quot; on registration module (see History of Change of registration).</description>
          <population>Full analysis set (FAS); FAS was defined as participants who were randomized and received at least one dose of the study drug.</population>
          <units>Percent of Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CM Fraction at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.40" spread="50.191"/>
                    <measurement group_id="O2" value="42.88" spread="134.849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CM Fraction at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.40" spread="54.049"/>
                    <measurement group_id="O2" value="-3.70" spread="56.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL Fraction at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.20" spread="16.087"/>
                    <measurement group_id="O2" value="5.29" spread="14.765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL Fraction at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.88" spread="17.551"/>
                    <measurement group_id="O2" value="2.37" spread="13.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Fraction at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.58" spread="10.413"/>
                    <measurement group_id="O2" value="2.39" spread="9.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Fraction at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.43" spread="9.993"/>
                    <measurement group_id="O2" value="3.07" spread="11.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Fraction at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.31" spread="5.517"/>
                    <measurement group_id="O2" value="1.80" spread="5.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Fraction at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.33" spread="6.567"/>
                    <measurement group_id="O2" value="1.37" spread="7.687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 8</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>TAK-085 4 g</title>
          <description>A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule was orally administered immediately after a meal twice daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

